Dogecoin Cash, Inc.

What they do

The company's principal operations are conducted through PrestoCorp, Inc. (dba PrestoDoctor), a telemedicine platform that connects patients with licensed physicians for medical cannabis evaluations via secure video consultations in states where permitted. It operates an asset-light model, providing the technology and administrative support while physicians are independent contractors. Substantially all revenue comes from these telemedicine consultations. The company also holds cannabis-related intellectual property and maintains digital asset-focused subsidiaries (Dogecoin Treasury, DogeSPAC, Meme Coins) that are not a principal source of revenue.

Revenue drivers

• Telemedicine consultation services (PrestoDoctor) — Generates substantially all revenue from facilitating medical cannabis evaluations between patients and licensed physicians through its proprietary platform, with quarterly revenue around $190,000.

Recent performance

For Q1 2026 (ended March 31, 2026), revenue was $192,898, up 5% from $184,473 in Q1 2025, despite competitive pressure. Gross profit improved to $126,179 (65% of sales) from $116,967 (63%) as cost of sales fell 1%. Net loss from continuing operations was $101,614, an improvement from a $174,791 loss in the prior year quarter, but total net loss was $200,470. Cash used in operating activities was $13,443, and cash on hand was only $19,510.

Strategy

The company aims to expand its telemedicine platform while maintaining a capital-efficient structure. It continues to evaluate digital asset and technology initiatives through subsidiaries, though these are not the primary revenue source. Management plans to raise capital through public or private offerings of equity or convertible debt to fund working capital and business plan execution, despite dilution to existing shareholders.

Risks

• Liquidity and going concern — Cash on hand of $19,510 is insufficient for current operations, and the company has an accumulated deficit of $84.6 million, raising substantial doubt about its ability to continue as a going concern.
• Dependence on telemedicine regulation — Revenue relies entirely on state laws permitting medical cannabis evaluations via telemedicine; changes in regulation could eliminate or restrict the company's primary revenue source.
• Intense competition — Management cites sustained competitive pressure in the cannabis telemedicine industry that has compressed demand growth through Q1 2026.
• Name confusion with cryptocurrency — The company is not affiliated with Dogecoin cryptocurrency and any association could lead to reputational or legal issues; crypto-related subsidiaries are largely exploratory and not contributing revenue.

Outlook

Management acknowledges that current cash is inadequate and plans to raise capital through equity or convertible debt offerings. They expect continued competitive pressure in the cannabis telemedicine industry, which may limit revenue growth. The company will need to secure additional funding to continue operations and execute its business plan.